| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
66,230,000 |
| Market
Cap: |
4.11(M) |
| Last
Volume: |
362,100 |
Avg
Vol: |
361,099 |
| 52
Week Range: |
$0.062 - $0.062 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Advaxis is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (Lm) Technology antigen delivery products based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Co.'s pipeline of product candidates include: ADXS-503, which is for the cancer indication of non-small cell lung cancer in combination with KEYTRUDA® (pembrolizumab); ADXS-504, which is for the cancer indication of early stage prostate cancer; and ADXS-PSA, which is for the cancer indication of metastatic prostate cancer in combination with KEYTRUDA® (pembrolizumab).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,317,716 |
1,317,716 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sidransky David |
Director |
– • – |
2015-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
100,419 |
|
- |
|
| Berman Richard J |
Director |
– • – |
2015-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
98,762 |
|
- |
|
| Patton James P |
Director |
– • – |
2015-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
207,290 |
|
- |
|
| Mckearn Thomas J |
Director |
– • – |
2015-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
100,220 |
|
- |
|
| Appel Roni |
Director |
– • – |
2015-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
123,810 |
|
- |
|
| Khleif Samir N |
Director |
– • – |
2015-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
66,157 |
|
- |
|
| Mauro David J |
Chief Medical Officer |
• – – |
2015-02-27 |
4 |
D |
$9.00 |
$288 |
D/D |
(32) |
140,998 |
|
- |
|
| Mauro David J |
Chief Medical Officer |
• – – |
2015-02-27 |
4 |
A |
$9.00 |
$1,224 |
D/D |
136 |
141,030 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2015-02-27 |
4 |
D |
$9.00 |
$252 |
D/D |
(28) |
109,531 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2015-02-27 |
4 |
A |
$9.00 |
$1,944 |
D/D |
216 |
109,559 |
|
- |
|
| Bonstein Sara |
Chief Financial Officer |
• – – |
2015-02-27 |
4 |
D |
$9.00 |
$252 |
D/D |
(28) |
93,798 |
|
- |
|
| Bonstein Sara |
Chief Financial Officer |
• – – |
2015-02-27 |
4 |
A |
$9.00 |
$1,368 |
D/D |
152 |
93,826 |
|
- |
|
| O'connor Daniel |
Chief Executive Officer |
• – – |
2015-02-27 |
4 |
A |
$9.00 |
$6,660 |
D/D |
740 |
356,892 |
|
- |
|
| Mayes Gregory T. |
Chief Operating Officer |
• – – |
2015-02-27 |
4 |
D |
$9.00 |
$189 |
D/D |
(21) |
138,343 |
|
- |
|
| Mayes Gregory T. |
Chief Operating Officer |
• – – |
2015-02-27 |
4 |
A |
$9.00 |
$1,629 |
D/D |
181 |
138,364 |
|
- |
|
| Bonstein Sara |
Chief Financial Officer |
• – – |
2015-02-24 |
4 |
D |
$8.30 |
$125,222 |
D/D |
(15,087) |
93,674 |
|
- |
|
| Gross Phillip |
10% Owner |
– – • |
2015-02-18 |
4 |
B |
$7.50 |
$5,135,715 |
I/I |
684,762 |
5,139,366 |
1.5 |
- |
|
| Mayes Gregory T. |
Chief Operating Officer |
• – – |
2015-01-30 |
4 |
D |
$9.85 |
$660 |
D/D |
(67) |
138,183 |
|
- |
|
| Mayes Gregory T. |
Chief Operating Officer |
• – – |
2015-01-30 |
4 |
A |
$9.85 |
$2,394 |
D/D |
243 |
138,250 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2015-01-30 |
4 |
D |
$4.03 |
$12,914 |
D/D |
(3,021) |
109,343 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2015-01-30 |
4 |
A |
$9.85 |
$2,876 |
D/D |
292 |
112,364 |
|
- |
|
| Mauro David J |
Chief Medical Officer |
• – – |
2015-01-30 |
4 |
D |
$9.85 |
$581 |
D/D |
(59) |
140,894 |
|
- |
|
| Mauro David J |
Chief Medical Officer |
• – – |
2015-01-30 |
4 |
A |
$9.85 |
$1,832 |
D/D |
186 |
140,953 |
|
- |
|
| O'connor Daniel |
Chief Executive Officer |
• – – |
2015-01-30 |
4 |
A |
$9.85 |
$9,791 |
D/D |
994 |
356,152 |
|
- |
|
| Bonstein Sara |
Chief Financial Officer |
• – – |
2015-01-30 |
4 |
D |
$9.85 |
$552 |
D/D |
(56) |
108,761 |
|
- |
|
465 Records found
|
|
Page 14 of 19 |
|
|
